Abstracts tagged "Rituximab"

Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
A. Lois-Iglesias¹, J. Ishorari² and D.A. Isenberg², ¹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…
Abstract Number: 459 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Ronald F. van Vollenhoven¹, Paul Emery², Clifton O. Bingham III³, Edward Keystone⁴, Roy Fleischmann⁵, Daniel Furst⁶, Nicola Tyson⁷, Abdul Mehbob⁸ and Patrica B. Lehane⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Department of Medicine, Johns Hopkins University, Baltimore, MD, ⁴The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ⁶Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁷Roche Products Limited, Welwyn Garden City, United Kingdom, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in RA patients (pts) in a global clinical trial program. Methods: Pooled observed case analysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].